Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs Twist Bioscience Corp — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $35.39, while Twist Bioscience Corp trades at $125.52 (market cap $8.26B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| NVDL | TWST | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $153.10 |
52-Week Low | $21.76 | $24.16 |
Market Cap | — | $8.26B |
Enterprise Value | — | $8.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.18, down 4.01% on the day. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETF has delivered 12.66% year-to-date returns through June 8, 2026, outperforming the S&P 500. Recent stock splits on June 25-26, 2026, adjusted the share structure.
The leveraged ETF offers amplified exposure to Nvidia's AI-driven growth but faces risks from daily reset mechanics and tracking divergence. With Nvidia continuing to beat earnings estimates and maintain AI leadership, NVDL provides tactical upside potential, though volatility compression and leverage decay remain significant concerns for long-term holders.
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
